DK2925782T3 - Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf - Google Patents
Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf Download PDFInfo
- Publication number
- DK2925782T3 DK2925782T3 DK13849989.2T DK13849989T DK2925782T3 DK 2925782 T3 DK2925782 T3 DK 2925782T3 DK 13849989 T DK13849989 T DK 13849989T DK 2925782 T3 DK2925782 T3 DK 2925782T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- procedures
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732452P | 2012-12-03 | 2012-12-03 | |
| US201361816788P | 2013-04-28 | 2013-04-28 | |
| US201361863106P | 2013-08-07 | 2013-08-07 | |
| US201361881523P | 2013-09-24 | 2013-09-24 | |
| US201361898710P | 2013-11-01 | 2013-11-01 | |
| PCT/IB2013/003164 WO2014087248A2 (en) | 2012-12-03 | 2013-12-03 | Anti-cd47 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2925782T3 true DK2925782T3 (da) | 2020-04-06 |
Family
ID=50588748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13849989.2T DK2925782T3 (da) | 2012-12-03 | 2013-12-03 | Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US11059910B2 (da) |
| EP (2) | EP3725807B1 (da) |
| JP (4) | JP6392770B2 (da) |
| CN (2) | CN105121467B (da) |
| AU (2) | AU2013353763B2 (da) |
| CA (2) | CA3155275A1 (da) |
| DK (1) | DK2925782T3 (da) |
| ES (1) | ES2784631T3 (da) |
| PT (1) | PT2925782T (da) |
| RU (2) | RU2019118257A (da) |
| WO (1) | WO2014087248A2 (da) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2925782T (pt) * | 2012-12-03 | 2020-04-22 | Novimmune Sa | Anticorpos anti-cd47 e métodos de utilização destes |
| BR112015013431A2 (pt) | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| WO2016022971A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
| CA2964173A1 (en) * | 2014-10-10 | 2016-04-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to eliminate cancer stem cells by targeting cd47 |
| AU2016225993B2 (en) * | 2015-03-04 | 2020-09-24 | Yuhan Corporation | Antibody therapeutics that bind CD47 |
| EP4070887A1 (en) * | 2015-04-21 | 2022-10-12 | Isolation Bio Inc. | Methods for high throughput microbiology applications |
| RU2748401C2 (ru) * | 2015-09-18 | 2021-05-25 | Арч Онколоджи, Инк. | Терапевтические антитела к CD47 |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| WO2017100462A2 (en) | 2015-12-11 | 2017-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of cd47 and egfr |
| US10927173B2 (en) | 2016-01-11 | 2021-02-23 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies |
| KR102833922B1 (ko) * | 2016-01-21 | 2025-07-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 면역조절제의 조합물에 의한 암의 치료 |
| CN106084052B (zh) * | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
| US12344669B2 (en) | 2016-06-17 | 2025-07-01 | Changchun Genescience Pharmaceutical Co., Ltd. | Anti-CD47 monoclonal antibody and use thereof |
| CA3035681A1 (en) | 2016-09-29 | 2018-04-05 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| EP3535299A1 (en) * | 2016-11-04 | 2019-09-11 | Novimmune S.A. | Anti-cd19 antibodies and methods of use thereof |
| US11352425B2 (en) | 2016-11-08 | 2022-06-07 | Absos, Llc | Anti-CD47 antibodies |
| SG10201913260VA (en) | 2016-11-18 | 2020-03-30 | Beijing Hanmi Pharmaceutical Co Ltd | Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same |
| JP6923875B2 (ja) | 2017-01-27 | 2021-08-25 | 東亞合成株式会社 | 腫瘍細胞のｃｄ４７発現を抑制するための薬剤組成物およびその利用 |
| CN113831417B (zh) | 2017-05-08 | 2024-10-01 | 上海津曼特生物科技有限公司 | 双特异性重组蛋白及其应用 |
| EP3630167A1 (en) | 2017-05-26 | 2020-04-08 | NovImmune SA | Anti-cd47 x anti-mesothelin antibodies and methods of use thereof |
| AU2018303254B2 (en) | 2017-07-21 | 2025-05-29 | Novimmune Sa | Generating multispecific antibody mixtures and methods of uses thereof |
| BR112020001679A2 (pt) * | 2017-08-02 | 2020-07-21 | Phanes Therapeutics, Inc. | anticorpos anti-cd47 e usos dos mesmos |
| CN111201031B (zh) * | 2017-08-25 | 2024-11-01 | 诺夫免疫股份有限公司 | 抗CD47 x抗间皮素抗体及其使用方法 |
| CN109422811A (zh) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| CN108503708B (zh) * | 2017-09-01 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd47抗体及其用途 |
| EA039662B1 (ru) * | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
| AU2018358004A1 (en) | 2017-11-01 | 2020-05-28 | Hummingbird Bioscience Pte. Ltd. | CD47 antigen-binding molecules |
| EA202091339A1 (ru) | 2017-12-01 | 2020-10-21 | Сиэтл Дженетикс, Инк. | Антитела против cd47 и их применение для лечения онкологических заболеваний |
| WO2019109876A1 (zh) * | 2017-12-04 | 2019-06-13 | 北京韩美药品有限公司 | 抗pd‐l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| CN120399075A (zh) | 2018-03-14 | 2025-08-01 | 诺维莫尼公司 | 抗-CD3ε抗体及其应用方法 |
| CN110305212A (zh) | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| CN112601555A (zh) * | 2018-05-09 | 2021-04-02 | 乐高化学生物科学股份有限公司 | 与抗cd19抗体药物结合物相关的组合物和方法 |
| KR20210029158A (ko) * | 2018-06-03 | 2021-03-15 | 람카프 바이오 베타 엘티디. | Ceacam5 및 cd47에 대한 이중특이성 항체 |
| CN112533954B (zh) * | 2018-08-08 | 2024-06-18 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向cd47和her2的重组双功能蛋白 |
| CN110885376B (zh) * | 2018-09-11 | 2020-10-09 | 上海洛启生物医药技术有限公司 | 抗cd47/cd20双特异性抗体及其用途 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CA3118312A1 (en) * | 2018-10-29 | 2020-05-07 | Tigatx, Inc. | Compositions and methods comprising iga antibody constructs |
| CA3118326A1 (en) | 2018-10-29 | 2020-05-07 | Umc Utrecht Holding B.V. | Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils |
| CA3132078A1 (en) | 2019-03-06 | 2020-09-10 | Jiangsu Hengrui Medicine Co., Ltd. | Bifunctional fusion protein and pharmaceutical use thereof |
| KR20220004979A (ko) | 2019-03-27 | 2022-01-12 | 유엠씨 우트레크트 홀딩 비.브이. | 조작된 iga 항체 및 사용 방법 |
| TW202104260A (zh) | 2019-04-05 | 2021-02-01 | 美商西建公司 | 腫瘤選擇性結合ｃｄ４７之抗體之工程 |
| EP3980747A1 (en) | 2019-06-07 | 2022-04-13 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| KR20220047277A (ko) | 2019-07-16 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| WO2021053587A1 (en) | 2019-09-18 | 2021-03-25 | Klaus Strein | Bispecific antibodies against ceacam5 and cd3 |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| WO2021078219A1 (en) * | 2019-10-25 | 2021-04-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel anti-cd47 antibodies and uses thereof |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| CN110724672B (zh) * | 2019-10-31 | 2020-06-16 | 浙江蓝盾药业有限公司 | 杂交瘤细胞株105d11、抗体及其应用 |
| EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| US20220411497A1 (en) * | 2019-12-17 | 2022-12-29 | Phanes Therapeutics, Inc. | Bispecific Antibodies with Alternatively Matched Interchain Cysteines and Uses Thereof |
| CN115397853A (zh) | 2019-12-17 | 2022-11-25 | 辉瑞大药厂 | 对cd47、pd-l1具特异性的抗体及其用途 |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| WO2021139687A1 (zh) * | 2020-01-09 | 2021-07-15 | 信达生物制药(苏州)有限公司 | 抗cd47抗体和抗cd20抗体的组合在制备用于预防或治疗肿瘤的药物中的应用 |
| MX2022009947A (es) | 2020-02-14 | 2022-11-07 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. |
| EP4127139A1 (en) | 2020-03-27 | 2023-02-08 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| WO2021213511A1 (en) * | 2020-04-24 | 2021-10-28 | Virtuoso Binco, Inc. | Bispecific antibodies for treating cd47-associated diseases |
| WO2021259902A1 (en) * | 2020-06-22 | 2021-12-30 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint |
| KR20230033647A (ko) | 2020-06-30 | 2023-03-08 | 멘두스 비.브이. | 난소암 백신에서 백혈병 유래 세포의 용도 |
| CN114457021A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达cd47抗体的多能干细胞及其衍生物与应用 |
| CN118878693A (zh) * | 2020-11-23 | 2024-11-01 | 康诺亚生物医药科技（成都）有限公司 | 一种双特异性抗体及其用途 |
| JP2023552375A (ja) | 2020-12-06 | 2023-12-15 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体 |
| JP2024501809A (ja) | 2020-12-18 | 2024-01-16 | ランカプ バイオ ベータ リミテッド | Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体 |
| JP2024510989A (ja) | 2021-03-12 | 2024-03-12 | メンドゥス・ベスローテン・フェンノートシャップ | ワクチン接種方法及びｃｄ４７遮断薬の使用 |
| IL305827A (en) | 2021-03-22 | 2023-11-01 | Novimmune Sa | Bispecific antibodies targeting CD47 and PD-L1 and methods of using them |
| AU2022241935A1 (en) | 2021-03-22 | 2023-09-28 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| WO2023006390A1 (en) * | 2021-07-30 | 2023-02-02 | Ludwig-Maximilians-Universität München | Mesothelin antibodies and use thereof |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| EP4452415A1 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4493592A1 (en) | 2022-03-14 | 2025-01-22 | LamKap Bio gamma AG | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| HUE069263T2 (hu) | 2022-03-17 | 2025-02-28 | Gilead Sciences Inc | Ikarosz cink-ujj család degradálói és azok alkalmazása |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| EP4499711A1 (en) * | 2022-03-25 | 2025-02-05 | WuXi Biologics Ireland Limited | Anti-her2/anti-cd47 molecules and uses thereof |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| EP4514851A1 (en) | 2022-06-16 | 2025-03-05 | LamKap Bio beta Ltd. | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
| PE20250758A1 (es) | 2022-07-01 | 2025-03-13 | Gilead Sciences Inc | Compuestos de cd73 |
| EP4554628A1 (en) | 2022-07-12 | 2025-05-21 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| KR20250122479A (ko) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025010272A1 (en) | 2023-07-03 | 2025-01-09 | Neoimmunetech, Inc. | Heterodimeric fc molecules and uses thereof |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0547065B1 (en) | 1990-06-29 | 2001-08-29 | Large Scale Biology Corporation | Melanin production by transformed microorganisms |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| CA2116107A1 (en) | 1991-09-05 | 1993-03-18 | George Y. Wu | Targeted delivery of poly-or oligonucleotides to cells |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| US5316264A (en) | 1993-07-07 | 1994-05-31 | Newman Sr Robert D | Flow-through telescoping pole |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US7531643B2 (en) | 1997-09-11 | 2009-05-12 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| JP2003247999A (ja) * | 2002-02-22 | 2003-09-05 | Bml Inc | 病理検体の判定システム |
| WO2004001384A2 (en) | 2002-06-25 | 2003-12-31 | The Regents Of The University Of California | Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
| CN101255196A (zh) * | 2002-06-28 | 2008-09-03 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| DE60305919T2 (de) | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
| JP4637749B2 (ja) * | 2003-11-11 | 2011-02-23 | 中外製薬株式会社 | ヒト化抗ｃｄ４７抗体 |
| US7273608B2 (en) | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| KR20080032097A (ko) * | 2005-06-20 | 2008-04-14 | 메다렉스, 인코포레이티드 | 씨디19 항체 및 그의 용도 |
| US20090191202A1 (en) * | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| CA2665287C (en) | 2006-10-06 | 2022-08-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Prevention of tissue ischemia, related methods and compositions |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| EP2207797A4 (en) | 2007-10-11 | 2010-12-22 | Univ Health Network | MODULATION OF THE SIRPALPHA CD47 INTERACTION TO IMPROVE TRANSPLANTATION OF HUMAN HEMATOPOETIC STEM CELLS AND COMPOUNDS THEREOF |
| JP5547656B2 (ja) * | 2008-01-15 | 2014-07-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| ES2545792T5 (es) | 2009-05-20 | 2018-09-14 | Novimmune Sa | Bancos de polipéptidos sintéticos y métodos para generar variantes de polipéptidos diversificados de forma natural |
| SI2477648T1 (sl) * | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| US9151760B2 (en) | 2009-09-29 | 2015-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| EP2513312B1 (en) | 2009-12-17 | 2015-03-18 | NovImmune SA | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
| WO2011076781A1 (en) | 2009-12-22 | 2011-06-30 | Novartis Ag | Tetravalent cd47-antibody constant region fusion protein for use in therapy |
| CA3138956A1 (en) | 2010-05-14 | 2011-11-17 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| US20130130276A1 (en) * | 2010-05-17 | 2013-05-23 | School Juridical Person Kitasato Institute | Method for detecting gastric cancer |
| US8506197B2 (en) | 2010-07-01 | 2013-08-13 | Thomas Howard Beaty | Cleaning or applicating apparatus and dispensing system |
| AU2011290480B2 (en) | 2010-08-16 | 2015-07-30 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| WO2012088309A1 (en) * | 2010-12-21 | 2012-06-28 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor |
| AU2012222463B9 (en) | 2011-03-02 | 2017-05-25 | Roche Glycart Ag | CEA antibodies |
| CN103596985B (zh) * | 2011-04-19 | 2016-06-08 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
| DK2768857T3 (da) | 2011-10-19 | 2020-02-03 | Novimmune Sa | Fremgangsmåder til oprensning af antistoffer |
| MY169341A (en) | 2012-02-06 | 2019-03-21 | Inhibrx Inc | Cd47 antibodies and methods of use thereof |
| PT2925782T (pt) * | 2012-12-03 | 2020-04-22 | Novimmune Sa | Anticorpos anti-cd47 e métodos de utilização destes |
| US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
| WO2015197582A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| EP3535299A1 (en) | 2016-11-04 | 2019-09-11 | Novimmune S.A. | Anti-cd19 antibodies and methods of use thereof |
-
2013
- 2013-12-03 PT PT138499892T patent/PT2925782T/pt unknown
- 2013-12-03 AU AU2013353763A patent/AU2013353763B2/en active Active
- 2013-12-03 RU RU2019118257A patent/RU2019118257A/ru unknown
- 2013-12-03 CN CN201380071851.9A patent/CN105121467B/zh active Active
- 2013-12-03 EP EP20152992.2A patent/EP3725807B1/en active Active
- 2013-12-03 US US14/095,395 patent/US11059910B2/en active Active
- 2013-12-03 CA CA3155275A patent/CA3155275A1/en active Pending
- 2013-12-03 WO PCT/IB2013/003164 patent/WO2014087248A2/en not_active Ceased
- 2013-12-03 CA CA2892585A patent/CA2892585C/en active Active
- 2013-12-03 JP JP2015544559A patent/JP6392770B2/ja active Active
- 2013-12-03 RU RU2015126533A patent/RU2693078C2/ru active IP Right Revival
- 2013-12-03 DK DK13849989.2T patent/DK2925782T3/da active
- 2013-12-03 CN CN201910489021.7A patent/CN110183534A/zh active Pending
- 2013-12-03 ES ES13849989T patent/ES2784631T3/es active Active
- 2013-12-03 EP EP13849989.2A patent/EP2925782B1/en active Active
-
2018
- 2018-06-22 US US16/015,610 patent/US20180291116A1/en not_active Abandoned
- 2018-06-22 US US16/015,601 patent/US11840553B2/en active Active
- 2018-06-22 US US16/015,592 patent/US20180355065A1/en not_active Abandoned
- 2018-08-23 JP JP2018156036A patent/JP2019023187A/ja not_active Withdrawn
- 2018-08-24 AU AU2018220150A patent/AU2018220150B2/en active Active
-
2020
- 2020-08-06 JP JP2020133628A patent/JP7563916B2/ja active Active
-
2022
- 2022-10-06 JP JP2022161544A patent/JP2022177319A/ja active Pending
-
2024
- 2024-01-08 US US18/406,975 patent/US20240400720A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2925782T3 (da) | Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK2812443T3 (da) | Cd47-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| DK3550836T3 (da) | Fremgangsmåde og anordning til afkodning | |
| DK2854883T3 (da) | Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf | |
| DK2968415T3 (da) | Cd123-specifik kimær antigenreceptor-omdirigerede t-celler og fremgangsmåder til anvendelse deraf | |
| DK2956175T3 (da) | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf | |
| DK3196022T3 (da) | Trykningssystem og fremgangsmåde | |
| DK2850202T3 (da) | Fremgangsmåder og grupper | |
| DK2917763T3 (da) | Lidar-målesystem og lidar-målefremgangsmåde | |
| DK2906684T3 (da) | T-celle-modificerende forbindelser og anvendelser deraf | |
| DK3831283T3 (da) | Analytsensorindretninger, forbindelser og fremgangsmåder | |
| DK3079719T3 (da) | ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3379339T3 (da) | Procespatron og billeddannende indretning | |
| BR112015007125A2 (pt) | aparelho e método | |
| DK2584921T3 (da) | Sondeernæringspakninger og fremgangsmåder til anvendelse deraf | |
| DE102012104039A8 (de) | Hubtoranordnung sowie Torsturz-Abdichteinrichtung hierfür | |
| DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
| DK2964767T3 (da) | Toksingener og fremgangsmåder til anvendelse deraf | |
| DK3930322T3 (da) | Fremgangsmåder og anordninger til kodning | |
| DK3381461T3 (da) | Peptider og fremgangsmåder til anvendelse deraf | |
| DK2908661T3 (da) | Mikroalgemelgranulater og fremgangsmåde til fremstilling deraf | |
| EP2939734C0 (en) | MIXING DEVICE AND METHOD | |
| DK2896694T3 (da) | Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| NO344969B1 (no) | Undervannsplassert anordning og fremgangsmåte |